Ocugen, Inc. Form 8-K Summary
Business Context and Reporting Period
Ocugen, Inc. filed a Form 8-K reporting matters from its September 21, 2026 Special Meeting of Stockholders. The filing was signed on September 22, 2026.
- The meeting was held virtually.
- 160,214,431 shares, representing 47.3% of shares outstanding as of the July 27, 2026 record date, were represented in person or by proxy, constituting a quorum.
Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
Stockholders were asked to approve an amendment increasing Ocugen’s authorized common stock by 250,000,000 shares. The filing does not state that the additional shares have been issued.
Material Changes Versus the Prior Comparable Period
No comparative financial information or prior-period operating results are included. The material corporate action was the adjournment of the vote on the authorized-share increase proposal.
Vote Results, Outlook, and Risks
Stockholders approved Proposal 2, authorizing an adjournment if necessary or appropriate to solicit additional proxies for Proposal 1.
| Proposal 2 Vote | Shares |
|---|---|
| For | 124,584,658 |
| Against | 33,639,820 |
| Abstentions | 1,989,953 |
The meeting was adjourned solely with respect to Proposal 1, which would amend the Sixth Amended and Restated Certificate of Incorporation, as amended, to increase authorized common stock by 250,000,000 shares. The adjourned meeting is scheduled for October 5, 2026, at 8:00 a.m. Eastern Time, at www.virtualshareholdermeeting.com/OCGN2026SM.
The July 27, 2026 record date remains applicable. Stockholders who already voted on Proposal 1 and do not wish to change their vote do not need to take further action.
Important Facts for Investors to Verify
- Verify the final vote on Proposal 1 at or after the October 5, 2026 adjourned meeting.
- Assess the potential dilution and capital-raising capacity associated with authorizing 250,000,000 additional common shares.
- Review subsequent filings for any issuance, financing, equity compensation, or other use of the newly authorized shares.
- Confirm that the meeting adjournment and record-date details remain unchanged.